130
Views
16
CrossRef citations to date
0
Altmetric
Review

Review of the current treatments for leishmaniases

, , &
Pages 69-77 | Published online: 27 Jul 2012

Abstract

Leishmaniases are vector-borne zoonotic diseases that are prevalent in tropical and subtropical areas in the world, with two million new cases occurring yearly. Visceral and tegumentary forms of leishmaniasis are known. The latter form may present as localized cutaneous or mucosal forms, disseminated, diffuse forms, or leishmaniasis recidiva cutis. Visceral leishmaniasis is caused by parasites of the species Leishmania (Leishmania) donovani and L. (L.) infantum, and tegumentary leishmaniasis is caused by 15 other species, with distinct distributions in the Old and New World. The varied clinical manifestations, the multitude of Leishmania species, and the increasing incidence of HIV coinfection make the diagnosis and treatment of leishmaniases complex. Since there are no solid data relating clinical manifestations, treatment outcomes and Leishmania species the decision regarding the best therapeutic option is almost entirely based on clinical manifestations. Because most of the literature is focused on leishmaniasis in the Old World, in this review we present data on the treatment of New World leishmaniasis in more detail. Ranked therapeutic options, clinical trials, and also observations, even with a restricted number of subjects, on treatment outcome of visceral and different forms of tegumentary leishmaniasis, are presented. Treatment for leishmaniasis in HIV-coinfected patients is addressed as well. Some of these data strongly suggest that the differences in the outcome of the treatment are related to the Leishmania species. Therefore, although it is not possible at most points of care to identify the species causing the infection – a process that requires a well equipped laboratory – the infecting species should be identified whenever possible. More recent approaches, such as the use of immunomodulators and immunotherapy, and the lines for development of new candidate drugs are mentioned.

Leishmaniases are vector-borne zoonotic diseases that are caused by various species of protozoa of the genus Leishmania. These pathogens are transmitted by phlebotomine sandflies and infect humans that are exposed to ecosystems where the vectors and reservoirs, either peridomestic or sylvatic, coexist. Anthroponotic cycles have been documented for some species of Leishmania and for defined geographical areas such as that of Leishmania (Leishmania) donovani in the Indian subcontinent and L. (L.) major in Afghanistan. Leishmaniases are prevalent in tropical and subtropical areas, with two million new cases occurring yearly.Citation1Citation3

Visceral and tegumentary forms of leishmaniasis are known. Visceral leishmaniasis (VL) is caused by L. (L.) donovani in the Indian subcontinent and East Africa and by L. (L.) infantum in other parts of Asia, Europe, Africa and the New World (where it was formerly referred to as L. (L.) chagasi). Tegumentary leishmaniasis (TL) is caused by approximately 15 species of parasites: L. (L.) major, L. (L.) tropica, L. (L.) aethiopica and sometimes L. (L.) infantum in the Old World and L. (Viannia) braziliensis, L. (L.) amazonensis, L. (V.) guyanensis, L. (V.) panamensis, L. (L.) mexicana, L. (L.) pifanoi, L. (L.) venezuelensis, L. (V.) peruviana, L. (V.) shawi, and L. (V.) lainsoni in the New World.Citation3,Citation4 Among species causing TL, different species of subgenus Viannia and L. (L.) amazonensis (subgenus Leishmania) are found from Mexico to Argentina, and the largest variety is present in Brazil, mainly in the Amazon region. L. (L.) mexicana is present in Mexico and other Central American countries.

Patients with active VL present with fever, hepatosplenomegaly, pancytopenia, hypergammaglobulinemia, and severe weight loss. The manifestations of TL are varied and are classified as localized cutaneous or mucosal forms, disseminated, diffuse forms, or leishmaniasis recidiva cutis;Citation5 some of these forms are related to particular species (). The localized cutaneous form is the initial lesion in most cases, and the progression to other forms depends on the species of Leishmania involved and on the host response.Citation5

Table 1 Clinical manifestations of leishmaniasis and related Leishmania species

The varied clinical manifestations, the multitude of Leishmania species, and the increasing incidence of HIV coinfection make the diagnosis and treatment of leishmaniases complex. The fact that there are no solid data relating clinical manifestations, treatment outcomes and Leishmania species the decision regarding the best therapeutic option is still based almost entirely on clinical manifestations. Although it is not possible at most points of care to identify the species causing the infection – a process that requires a well equipped laboratory – the infecting species should be identified whenever possible, because differences in treatment outcomes have been reported for localized cutaneous leishmaniasis (CL) caused by L. (V.) braziliensis and L. (V.) guyanensis.Citation6Citation8

Because most of the literature is focused on leishmaniasis in the Old World, herein we present data on the treatment of New World leishmaniasis in more detail.

Compounds in current use for the treatment of leishmaniasis

Pentavalent antimonials

Over the past 70 years, the first-choice drugs for the treatment of leishmaniasis have been pentavalent antimony compounds, which are available in two formulations, methylglucamine antimoniate and sodium stibogluconate.Citation9 The mechanism of action of pentavalent antimonials is still not well understood, but the drugs inhibit the activity of the glycolytic and oxidative pathways of fatty acids in amastigotes.Citation10 The most frequent side effects of pentavalent antimonials are arthralgia, myalgia, anorexia, headache, fever, vomiting, and dizziness. These drugs are toxic to the heart, kidneys, liver, and pancreas, and this toxicity represents an important limitation in the use of these drugs by pregnant women, the elderly, and individuals with cardiac disease, renal disease, or liver alterations.Citation5

Amphotericin B

Amphotericin B, a polyenic antibiotic with leishmanicidal activity, acts both on promastigotes and amastigotes and targets ergosterol in the surface membrane of the parasite, leading to increased permeability and the influx of ions.Citation11 There are four formulations of amphotericin B for clinical use: deoxycholate amphotericin B, liposomal amphotericin B, amphotericin colloidal dispersion, and amphotericin B lipid complex.Citation5,Citation10 Deoxycholate amphotericin B causes more severe adverse effects that include nausea, vomiting, fever, hypokalemia, renal failure, anemia, and heart problems. The cardiotoxicity, nephrotoxicity, and hypokalemia induced by this drug formulation and its intravenous delivery restrict its use to the hospital environment.Citation5,Citation12 Liposomal amphotericin B is more expensive; however, it reaches higher peak plasma levels, exhibits a shorter circulating half-life, and reaches higher concentrations in the liver and spleen, with much less toxicity than conventional amphotericin B. The lipid component drives the drug into the intracellular milieu, favoring the interaction with ergosterol of the parasite over host cholesterol.Citation13

Pentamidine

Pentamidine is a dibenzamidine that interferes with the synthesis of Leishmania DNA acting on the kinetoplast and on the mitochondrial membrane, leading to the death of the parasite. The primary adverse effects are hypotension, myalgia, abscess at the injection site, hypoglycemia, and diabetes mellitus.Citation5,Citation8,Citation10

Miltefosine

Initially developed for the treatment of cancer, miltefosine inhibits phospholipid and sterol biosynthesis and both in vitro and in vivo Leishmania. The limitation for its use is its toxicity to the gastrointestinal, hepatic, and renal systems. It is also teratogenic, which restricts its use in pregnant women.Citation5,Citation8

Paromomycin

Paromomycin is a broad spectrum aminoglycoside antibiotic that was found to have leishmanicidal activity in the 1960s. The main side effects are ototoxicity and local pain upon injection.Citation8,Citation10 The drug supposedly affects plasma membrane fluidity, interferes with ribosomes and mitochondrial membrane potential, inhibiting respiration.Citation14

Imidazoles/triazoles (ketoconazole, fluconazole, itraconazole)

These antifungal drugs include two distinct classes of compounds: imidazoles (eg, ketoconazole) and triazoles (eg, fluconazole and itraconazole). These two classes of compounds share the same antifungal spectrum and the same mechanism of action, but the metabolism of triazoles is slower. In addition, triazoles interfere less with sterol synthesis in humans and are thus less toxic than imidazoles. A great advantage of the azoles used in leishmaniases is their oral use and lower toxicity relative to pentavalent antimonials.Citation15

Treatment of leishmaniasis

There are few drugs available for the treatment of leishmaniasis as listed in the .

Table 2 Medicines with doses used to treat tegumentary and visceral leishmaniasesTable Footnotea

VL

VL is caused by two distinct species of Leishmania. Concerning clinical manifestations, only L. (L.) donovani infection can evolve into post-kalazar dermal leishmaniasis (PKDL), which is characterized by the appearance of cutaneous lesions containing parasites in the period after treatment of VL.Citation16

The drug used to treat active VL is chosen based on risk factors, patient characteristics, geographical area, and Leishmania species.

Pentavalent antimonials (sodium stibogluconate or meglumine antimoniate) are the first-line drugs used to treat VL.Citation17 In the New World, mainly in Brazil, the efficacy of these drugs is higher than 90%,Citation18 whereas treatment failure is approximately 60% in Bihar, India, and in Nepal.Citation19,Citation20 When treatment failure occurs or when there are restrictions, alternative drugs are used.

The second-choice drugs are the different formulations of amphotericin B, which have been shown to be effective against different species of Leishmania from different geographical areas, exhibiting high efficacy and low toxicity.Citation19,Citation21 In the Indian subcontinent and Europe, liposomal amphotericin B has been used as a first-line drug due to the resistance to anti-monials in some areas;Citation20 liposomal amphotericin B is used in the United States of America because it is the only treatment approved by the Food and Drug Administration. Recently a single-dose treatment with liposomal amphotericin B was tried in India, with 95% cure.Citation22 In the New World, mainly in Brazil, amphotericin B has been used successfully to treat VL in particular situations, primarily in older patients, children, transplant recipients, and patients with comorbidities such as diabetes and HIV infection.Citation18

Miltefosine, another alternative drug, is used to treat VL in the Indian subcontinent,Citation23,Citation24 where it exhibits high efficacy; it is used primarily to treat moderate VL. In contrast, in the New World, miltefosine was shown to be less effective than a pentavalent antimonial in a clinical trial that had to be discontinued (personal communication). Systemic paromo-mycin is a new option to treat VL in the Indian subcontinent and exhibits high efficacy.Citation25,Citation26 In East Africa, the efficacy of paromomycin was found to be lower, and therefore it is recommended that a higher dose be used or that the drug be used in combination with a pentavalent antimonial.Citation27 There has been no trial with paromomycin in the New World to date.

The evaluation of clinical recovery during and after treatment is based on the remission of fever, the reduction of splenomegaly and hepatomegaly, and the improvement of hematological disturbances.Citation3 There is no consensus regarding the parasitological or immunological methods that should be used to evaluate treatment success, but such methods are used in some centers to determine whether patients have been cured. The cure rate is typically 90%–95%, and the endpoint of the follow-up period to assess relapse is 6 months after treatment.Citation3 For relapses, the second-choice drugs and combinations of different drugs are used. Another complication is the appearance of PKDL in 5%–10% of patients after the apparent cure of VL caused by L. (L.) donovani;Citation16 the appearance of PKDL is not considered a relapse, and PKDL is treated with the same drug as used to treat VL but for an extended duration.Citation3

The recommendation of HIV testing in patients with recent VL diagnosis should be emphasized because the treatment response in coinfected patients is poorer than in noncoinfected patients.

CL of the Old World

In the Old World, CL caused by L. (L.) major has been treated with local paromomycin/methylbenzethonium chloride ointment, intralesional antimonials, and cryotherapy or thermotherapy when the lesion is small and not disfiguring or disabling, and when the patient is not immunosuppressed. When the disease is caused by the species L. (L.) tropica, L. (L.) aethiopica, or L.(L.) infantum, the preferred local treatment is intralesional antimonials alone or thermotherapy or cryotherapy alone. When systemic treatment is required, the choices are fluconazole or pentavalent antimonials plus pentoxifylline.Citation3,Citation28 For the treatment of leishmaniasis recidiva cutis caused by L. (L.) tropica, the use of pentavalent anti-monials plus oral allopurinol is recommended. For the treatment of diffuse CL caused by L. (L.) aethiopica, pentavalent antimonials plus intramuscular paromomycin are used.Citation3,Citation28

CL of the New World

Local treatment in clinical trials using paromomycin in different formulations have shown varied results, from a 64% cure rate in ColombiaCitation29 to an 88.6% cure rate in a double-blind study in Guatemala; the difference in the cure rates may be related to the Leishmania species that are prevalent in each area. Currently, the topical treatment of CL in the New World is not recommended, except in cases of infection with L. (L.) mexicana or in areas where the severe forms of the disease are very rare, as in Venezuela and Colombia.Citation30

The use of pentavalent antimonials resulted in a 5% therapeutic failure rate among cases of CL caused by L. (V.) braziliensis.Citation29 It was observed that 7%, 16%, and 39% of patients were refractory to treatment in Brazil, Bolivia, and Colombia, respectively; the infecting species were not identified in these studies.Citation31,Citation32 A randomized study that compared drugs showed that 40% of patients with CL caused by L. (V.) braziliensis who were treated exclusively with an antimonial required more than two or three courses of treatment to achieve a cure.Citation33,Citation34 Although spontaneous remission has been reported in the literature, it is infrequent among cases of CL caused by L. (V.) braziliensis, and there is a risk that the patient will develop mucosal leishmaniasis (ML) if no treatment is given. Costa et alCitation35 reported the results of clinical evaluations carried out over a period of 14 years in field clinics in the communities of Três Braços and Corte de Pedra, Bahia, Brazil involving 1416 patients with TL caused predominantly by L. (V.) braziliensis. Most of these patients received antimonial treatment, but 16 male patients refused treatment, and six pregnant female patients were not treated. During the patient follow-up period of 4–12 years, the observed healing time was 6 months for nine patients (40.9%); complete healing after 12 months was observed for19 patients (86.3%), and no healing after 12 months was observed in three (13.6%) cases.Citation35

In some studies, liposomal amphotericin B has been used to treat patients with CL caused by L.(V.) guyanensis,Citation36 L. (V.) braziliensis,Citation37 L. (L.) infantum,Citation38 or L. (L.) aethiopica.Citation39 However, larger studies are needed to assess the effectiveness of amphotericin B for the treatment of CL.Citation40

Pentamidine has been used successfully in areas endemic for CL due to L. (V.) guyanensis (4 mg/kg on days 1 and 4).Citation41 The rate of treatment failure depends on when the treatment was started; a 5% failure rate was observed when the treatment was started within the first month of disease, and a 25% failure rate was observed when treatment was started later.Citation41 In areas where infections are caused by L. (V.) braziliensis, L. (V.) shawi and L. (V.) guyanensis, the use of three intramuscular doses of 4 mg/kg on days 1, 3, and 5 is recommended, not exceeding a maximum dose of 300 mg/day. The effectiveness of this regimen was similar to that of 20-day antimonial treatment, reaching a 70%–75% cure rate; a lower dose and a shorter duration resulted in a 35% cure rateCitation42 or liposomal amphotericin B.

Miltefosine was used initially in 2005 in Colombia for the treatment of TL.Citation15 In Bolivia, oral miltefosine (2.5 mg/kg/28 days) was compared with an intramuscular antimonial (20 mg/kg/20 days) to treat TL caused by L. (V.) braziliensis,Citation43 and the cure rates after 6 months were 88% (36/41) and 94% (15/16), respectively. In Colombia, where L. (V.) panamensis is common, the same dose of oral miltefosine resulted in a 91% cure rate, similar to the cure rate for antimonials, whereas the cure rate of the placebo group was 38%.Citation44 In Guatemala, where L. (V.) braziliensis and L. (L.) mexicana predominate, the cure rate for miltefosine was only 53%, significantly lower than the cure rate for antimonials.Citation44 Thus, further studies are needed to specifically assess the value of miltefosine in the treatment of TL in the New World and to investigate the activity of miltefosine against different Leishmania species.

Regarding azoles, studies in Guatemala (N = 120 patients) and Belize (N = 8) assessed the efficacy of a 28-day regimen of oral 600 mg ketoconazole and found a lower cure rate (30% and 25%, respectively) among patients infected with L.(V.) braziliensis compared with the rate among patients infected with L. (L.) mexicana (89% and 100%, respectively). Moreover, among patients infected with L. (V.) panamensis, ketoconazole seemingly has a performance similar to that of antimonials.Citation45 However, the interpretation of these data should take into account the fact that CL caused by L. (L.) mexicana and L.(V.) panamensis has a high spontaneous cure rate.Citation45

Drug combinations that include pentavalent antimonials have been recommended in an attempt to increase the efficacy, reduce the dose, and decrease the prevalences of side effects and therapeutic failure.

ML

The frequency of ML varies according to the Leishmania species involved and to the geographical region. Andean countries have one of the highest frequencies of ML, with an average incidence of 7.1%.Citation30 Only systemic drugs are used for the treatment of ML. The cure rates are variable and depend on the geographical area, the Leishmania species involved, and the drug used for treatment.Citation46,Citation47

Pentavalent antimonials are the most used drugs to treat ML around the world. Different doses have been evaluated, and doses other than the recommended dose are occasionally used; however, the decision to use a different dose must be based on structured studies within the same area and with the same Leishmania species.Citation48,Citation49 The cure rate after treatment using pentavalent antimonials varies from 30% to 90%.Citation50

Because some reports using liposomal amphotericin B formulations for the treatment of ML have shown excellent results, liposomal amphotericin B can be an alternative treatment; however, the optimal doses for the treatment of ML have not been completely defined.Citation51 The use of pentamidine has been evaluated in Brazil, and healing was observed in nine (90%) of the ten patients who received 2140 mg and were followed up for 7.7 months.Citation50 Although the results are promising, few studies have been conducted to confirm this drug’s effectiveness due to its severe adverse effects and the discontinuity of drugs.

Miltefosine was used to treat ML in Bolivia, showing cure rates of 71% and 74% in patients treated for fourCitation52 and sixCitation53 weeks, respectively. However, the secure rates are lower than that for amphotericin B but similar to that for pentavalent antimonials.

Criteria of cure and follow up

There is no consensus on the criteria of cure in the literature, and this fact results in some controversial data seen in reported cure rate upon treatment. It would be desirable to have standardized criteria to be used in different studies based on clinical, parasitological parameters and the follow up time. In Brazil only the clinical criteria are considered, since other parameters are not satisfactory for this purpose. CL is considered cured when total epithelialization of the lesion and absence of any induration at the base of the ulcer are achieved within 3 months of treatment. ML is considered cured when regression of all clinical signs is achieved within 6 months of treatment. When these criteria are not reached, it is considered a relapse.Citation54

Leishmania/HIVcoinfection

HIV is present worldwide and is gradually spreading into areas endemic for leishmaniasis, leading to the appearance of Leishmania/HIV coinfection. The interaction of these two infections accelerates both disease processes, worsening the prognosis of both.Citation3,Citation55,Citation56

More data concerning treatment are available for coinfected patients with VL, mainly from the Old World. Therefore, more studies of patients with TL are needed because this form is more frequent in the New World, accounting for approximately 63% of coinfected patients.Citation57

For the treatment of VL in HIV-infected patients, the same drugs as used to treat noncoinfected patients are used. Coinfected patients more often experience adverse events, treatment failures, and relapses than immunocompetent individuals.Citation3,Citation55,Citation56 Cardiotoxicity, nephrotoxicity, and pancreatic damage are responsible for interruptions in treatment.Citation56,Citation58,Citation59

Varied cure rate has been observed in HIV-coinfected patients treated with pentavalent antimonials. In Ethiopia cure rate was 58.3%Citation60 and 58.6%,Citation61 while in Brazil it reached 68.4% (personal data). When used as rescue treatment upon treatment failure with liposomal amphotericin B presented, the cure rate reaches 83%. However, in this group, high mortality was observed, probably due to the adverse effects of pentavalent antimonials.Citation59

Liposomal amphotericin B in different doses has been used to treat VL in HIV-infected patients. When liposomal amphotericin B was used at a total dose of 30 mg/kg, an initial cure rate of 59.8% was observed.Citation59 In India, using a total dose of 20–24 mg/kg, the cure rate was 74.5%,Citation62 and in Brazil using the same dose it reached 63% (personal data).

Miltefosine has been used in Ethiopia, and the cure rate was 46% in HIV-coinfected patients.Citation61

Systemic treatment with paromomycin exhibited good efficacy among HIV-positive patients with VL in the Indian subcontinent (94%) and Ethiopia; however, the efficacy of this treatment in Sudan was low. The efficacy and safety of systemic paromomycin are still unknown in other areas.Citation63

Pentamidine was previously used for the treatment of VL, but due to resistance in the Indian subcontinent, its use was abandoned.Citation63 Currently, the use of pentamidine as a prophylactic agent is accepted because it is easy to administer, causes few adverse events, and exhibits minimal interference with antiretroviral therapy.Citation3 However, clinical trials are still needed to demonstrate the efficacy of pentamidine as a secondary prophylactic agent in HIV-positive patients.

The cure rate in VL patients coinfected with HIV is always lower than in HIV-negative patients, independent of whether they are treated with pentavalent antimonials or liposomal amphotericin B.

Because it has been reported that the efficacy of liposomal amphotericin B is limited, it has been proposed that higher doses be used to prevent resistance and to achieve a better cure rate;Citation21 high doses can be used because of the low frequency of adverse events such as nephrotoxicity.Citation55,Citation64

Antiretroviral treatment, which promotes increases in the CD4+ T cell count and decreases in the viral load in HIV-positive patients, is suggested to have an anti-Leishmania effect.Citation58 Even when the CD4+ T cell count is restored, secondary prophylaxis for VL is necessary for a long period to prevent relapses in coinfected patients. The reduction of the incidence of VL, the high survival rate of patients, high relapse rates, and possible immune reconstitution inflammatory syndrome are some impacts of antiretroviral therapy on VL.Citation3 Further, combining antiretroviral therapy with anti-Leishmania drugs seemingly prevents resistance, increases tolerance and efficacy, and reduces the duration and cost of VL treatment.Citation65

Among patients with TL, poorer responses to standard treatment and frequent relapses have been reported.Citation66,Citation67 The cure rate of TL is variable and depends on immune status and the Leishmania species that is present. Recently, Guerra et alCitation68 showed that the poor response to pentavalent antimonial treatment in co-infected patients was related to the high prevalence of L. (V.) guyanensis in the Amazon region. In the Old World, poor responses to pentavalent antimonials have been observed among HIV-infected patients with CL caused by L. (L.) tropica.Citation65 Independent of the Leishmania species, poor response to treatment is observed among HIV-infected patients, especially among those who are severely immunosuppressed.

Future of the treatment for leishmaniasis

To improve the treatment, different approaches have been evaluated, which include the use of immunomodulators and immunotherapy. For these approaches, basic information on the immune response and its progression during the disease course in leishmaniases patients is important.

During active CL, there is a predominance of CD4+ T cell response, and upon treatment the production of interferon-gamma increases while that of IL-10 decreases.Citation69 However, in ML, a high level of tumor necrosis factor (TNF)-α is observed during active lesion, which decreases with therapy.Citation70 Therefore, cytokines and inflammatory response modulators have been used in combination with other drugs, showing promising results. Pentoxifylline, an inhibitor of TNF-α, and imiquimod, an activator of Toll-like receptor 7 and a mediator of inflammatory cytokine production, have been used in association with antimonials to treat TL showing, respectively, reduction in the time to cureCitation71,Citation72 or increase of cure rate to 90% in patients refractory to antimonials.Citation73,Citation74 Association of inteferon-γ with antimonials is also effective in curing TL patients presenting resistance to antimonials.Citation75 Topical recombinant human granulocyte-macrophage colony-stimulating factor in combination with antimonials was also shown to reduce the healing time 50%.Citation76

As immunotherapy, Leishmania antigen, whole promastigote preparations, recombinant Leishmania antigens as Leish-111f, alone or in combination with adjuvants such as bacillus Calmette-Guerin (BCG) and monophosphoryl lipid A,Citation77 have shown promising results.Citation78 Immunotherapy in association with drugs is an option to preclude toxicity and emergence of resistance related to some drugs. Only in Venezuela is immunotherapy with whole promastigote preparation with BCG as adjuvant in current use to treat CL.Citation79,Citation80

The development of new candidate drugs is in progress, following mainly three lines. One focuses on plants as a source of anti-protozoal molecules, the other explores metabolic pathways of the parasite to find the target and to develop synthetic compounds,Citation81 and the more immediate approach is the repositioning of the medicines already on the market for other purposes. From the latter approach, amphotericin B, miltefosine, and pentoxifyilline, for example, have been previously developed, and presently, tamoxifen, a drug used for breast cancer, is being studied.Citation82

Acknowledgments

Financial support of Laboratorio de Investigação Médica (LIM-38) do Hospital das Clínicas da Faculdade de Medicina, USP and Conselho Nacional de Pesquisa (research fellowship to HG).

Disclosure

The authors report no conflicts of interest in this work.

References

  • DesjeuxPLeishmaniasis: current situation and new perspectivesComp Immunol Microbiol Infect Dis200427530531815225981
  • FauldeMSchraderJHeylGAmirihMDifferences in transmission seasons as an epidemiological tool for characterization of anthroponotic and zoonotic cutaneous leishmaniasis in northern AfghanistanActa Trop2008105213113818068684
  • World Health Organization (WHO)Control of Leishmaniases: report of a meeting of the WHO Expert CommitteeGenevaWHO2010
  • BanulsALHideMPrugnolleFLeishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humansAdv Parasitol200764110917499100
  • GotoHLindosoJACurrent diagnosis and treatment of cutaneous and mucocutaneous leishmaniasisExpert Rev Anti Infect Ther20108441943320377337
  • ArevaloJRamirezLAdauiVInfluence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasisJ Infect Dis2007195121846185117492601
  • RomeroGAGuerraMVPaesMGMacedoVOComparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniateAm J Trop Med Hyg200165545646511716098
  • SeifertKStructures, targets and recent approaches in anti-leishmanial drug discovery and developmentOpen Med Chem J20115313921629509
  • MarsdenPDJonesTCClinical manifestations, diagnosis and treatment of cutaneous leishmaniasisChangK-PBrayRSAmsterdamElsevier Science1985
  • CroftSLSeifertKYardleyVCurrent scenario of drug development for leishmaniasisIndian J Med Res2006123339941016778319
  • EllisMBernsenRAli-ZadehHA safety and feasibility study comparing an intermittent high dose with a daily standard dose of liposomal amphotericin B for persistent neutropenic feverJ Med Microbiol200958Pt 111474148519589901
  • MarsdenPDPersonal experience with diagnostic and therapeutic aspects of human Leishmania (Viannia) braziliensis in Tres BracosMemorias do Instituto Oswaldo Cruz19948934854877476237
  • BermanJDHuman leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 yearsClin Infect Dis19972446847039145744
  • MaaroufMde KouchkovskyYBrownSPetitPXRobert-GeroMIn vivo interference of paromomycin with mitochondrial activity of LeishmaniaExp Cell Res199723223393489168810
  • MitropoulosPKonidasPDurkin-KonidasMNew World cutaneous leishmaniasis: updated review of current and future diagnosis and treatmentJ Am Acad Dermatol201063230932220303613
  • ZijlstraEEMusaAMKhalilEAel-HassanIMel-HassanAMPost-kala-azar dermal leishmaniasisLancet Infect Dis200332879812560194
  • MurrayHWBermanJDDaviesCRSaraviaNGAdvances in leishmaniasisLancet200536694961561157716257344
  • Brazil. Ministry of HealthSecretary of Health Surveillance. Visceral leishmaniasis, clinical recommendations for the reduction of mortality2nd edBrasíliaMinistry of Health782009 Available at: portal.saude.gov.br/portal/arquivos/.../lv_reducao_letalidade_web.pdf
  • AlvarJCroftSOlliaroPChemotherapy in the treatment and control of leishmaniasisAdv Parasitol20066122327416735166
  • SundarSDrug resistance in Indian visceral leishmaniasisTrop Med Int Health200161184985411703838
  • BernCAdler-MooreJBerenguerJLiposomal amphotericin B for the treatment of visceral leishmaniasisClin Infect Dis200643791792416941377
  • SundarSChakravartyJAgarwalDRaiMMurrayHWSingle-dose liposomal amphotericin B for visceral leishmaniasis in IndiaN Engl J Med2010362650451220147716
  • BermanJDDevelopment of miltefosine for the leishmaniasesMini Rev Med Chem20066214515116472183
  • CroftSLSundarSFairlambAHDrug resistance in leishmaniasisClin Microbiol Rev200619111112616418526
  • SundarSChakravartyJParomomycin in the treatment of leishmaniasisExpert Opin Investig Drugs2008175787794
  • DavidsonRNden BoerMRitmeijerKParomomycinTrans R Soc Trop Med Hyg2009103765366018947845
  • HailuAMusaAWasunnaMGeographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trialPLoS Negl Trop Dis2010410e70921049059
  • GonzalezUPinartMReveizLAlvarJInterventions for Old World cutaneous leishmaniasisCochrane Database Syst Rev20084CD00506718843677
  • SotoJMToledoJTGutierrezPTreatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot studyAm J Trop Med Hyg200266214715112135285
  • DaviesCRReithingerRCampbell-LendrumDFeliciangeliDBorgesRRodriguezNThe epidemiology and control of leishmaniasis in Andean countriesCad Saude Publica200016492595011175518
  • Oliveira-NetoMPSchubachAMattosMGoncalves-CostaSCPirmezCA low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years)Am J Trop Med Hyg19975766516559430521
  • PalaciosROsorioLEGrajalewLFOchoaMTTreatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia speciesAm J Trop Med Hyg2001643–418719311442216
  • RochaPNAlmeidaRPBacellarODown-regulation of Th1 type of response in early human American cutaneous leishmaniasisJ Infect Dis199918051731173410515843
  • SantosJBde JesusARMachadoPRAntimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled studyJ Infect Dis2004190101793179615499535
  • CostaJMValeKCFrancaFSpontaneous healing of leishmaniasis caused by Leishmania viannia braziliensis in cutaneous lesionsRev Soc Bras Med Trop19902342052082133585
  • AmatoVSRabelloARotondo-SilvaASuccessful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patientsActa tropica200492212713215350864
  • BrownMNoursadeghiMBoyleJDavidsonRNSuccessful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasisBr J Dermatol2005153120320516029352
  • ParadisiACapizziRZampettiAAtypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin BJ Infect2005515e261e26415936088
  • RappCImbertPDarieHLiposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniateBull Soc Pathol Exot200396320921114582297
  • YardleyVCroftSLA comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasisInt J Antimicrob Agents200013424324810755238
  • LightburnEMorandJJMeynardJBManagement of American cutaneous leishmaniasis. Outcome apropos of 326 cases treated with high-dose pentamidine isethionateMed Trop (Mars)2003631354412891748
  • AndersenEMCruz-SaldarriagaMLlanos-CuentasAComparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasisAm J Trop Med Hyg200572213313715741547
  • SotoJReaJBalderramaMEfficacy of miltefosine for Bolivian cutaneous leishmaniasisAm J Trop Med Hyg200878221021118256415
  • SotoJAranaBAToledoJMiltefosine for new world cutaneous leishmaniasisClin Infect Dis20043891266127215127339
  • JolliffeDSCutaneous leishmaniasis from Belize – treatment with ketoconazoleClin Exp Dermatol198611162683708895
  • FrankeEDWignallFSCruzMEEfficacy and toxicity of sodium stibogluconate for mucosal leishmaniasisAnn Intern Med1990113129349402173461
  • AmatoVSTuonFFImamuraRAbegao de CamargoRDuarteMINetoVAMucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in BrazilJ Eur Acad Dermatol Venereol20092391026103419453817
  • Oliveira-NetoMPMattosMPirmezCMucosal leishmaniasis (“espundia”) responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, BrazilRev Inst Med Trop Sao Paulo200042632132511136518
  • de Oliveira-NetoMPMattos MdaSSuccessful therapeutic response of resistant cases of mucocutaneous leishmaniasis to a very low dose of antimonyRev Soc Bras Med Trop200639437637817119754
  • AmatoVSTuonFFBachaHANetoVANicodemoACMucosal leishmaniasis. Current scenario and prospects for treatmentActa Trop200810511917884002
  • AmatoVSTuonFFCamargoRASouzaRMSantosCRNicodemoACCan we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?Am J Trop Med Hyg201185581881922049033
  • SotoJToledoJValdaLTreatment of Bolivian mucosal leishmaniasis with miltefosineClin Infect Dis200744335035617205440
  • SotoJReaJValderramaMEfficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in BoliviaAm J Trop Med Hyg200981338738919706901
  • Brazil. Ministry of HealthSecretary of Health Surveillance. Guideline on Surveillance of American Tegumentary Leishmaniasis2nd edBrasíliaMinistry of Health1802010 Available at: portal.saude.gov.br/portal/arquivos/pdf/manual_lta_2ed.pdf
  • CruzINietoJMorenoJCanavateCDesjeuxPAlvarJLeishmania/ HIV co-infections in the second decadeIndian J Med Res2006123335738816778317
  • AlvarJCanavateCGutierrez-SolarBLeishmania and human immunodeficiency virus coinfection: the first 10 yearsClin Microbiol Rev19971022983199105756
  • RabelloAOrsiniMDischJLeishmania/HIV co-infection in Brazil: an appraisalAnn Trop Med Parasitol200397Suppl 1172814678630
  • AlvarJAparicioPAseffaAThe relationship between leishmaniasis and AIDS: the second 10 yearsClin Microbiol Rev2008212334359 table of contents18400800
  • RitmeijerKter HorstRChaneSLimited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalenceClin Infect Dis20115312e152e15822016502
  • HailuWWeldegebrealTHurissaZSafety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infectionTrans R Soc Trop Med Hyg20101041170671220870258
  • RitmeijerKDejenieAAssefaYA comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infectionClin Infect Dis200643335736416804852
  • SinhaPKvan GriensvenJPandeyKLiposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, IndiaClin Infect Dis2011537e91e9821890763
  • den BoerMLAlvarJDavidsonRNRitmeijerKBalasegaramMDevelopments in the treatment of visceral leishmaniasisExpert Opin Emerg Drugs200914339541019708817
  • van GriensvenJBalasegaramMMeheusFAlvarJLynenLBoelaertMCombination therapy for visceral leishmaniasisLancet Infect Dis201010318419420185097
  • SoniPPrasadNKhandelwalKUnresponsive cutaneous leishmaniasis and HIV co-infection: report of three casesIndian J Dermatol Venereol Leprol2011772251
  • GuimaraesLHMachadoPRLagoELAtypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, BrazilTrans R Soc Trop Med Hyg2009103771271519481233
  • LindosoJABarbosaRNPosada-VergaraMPUnusual manifestations of tegumentary leishmaniasis in AIDS patients from the New WorldBr J Dermatol2009160231131819187345
  • GuerraJACoelhoLIPereiraFRAmerican tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian AmazonAm J Trop Med Hyg201185352452721896816
  • Gomes-SilvaAde Cassia BittarRDos Santos NogueiraRCan interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?Clin Exp Immunol2007149344044417614975
  • Ribeiro de JesusALunaTPacheco de AlmeidaRMachadoPRCarvalhoEMPentoxifylline down modulate in vitro T cell responses and attenuate pathology in Leishmania and HTLV-I infectionsInt Immunopharmacol20088101344135318687297
  • MachadoPRLessaHLessaMOral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasisClin Infect Dis200744678879317304449
  • Miranda-VerasteguiCTullianoGGyorkosTWFirst-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimonyPLoS Negl Trop Dis200937e49119636365
  • LessaHAMachadoPLimaFSuccessful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimonyAm J Trop Med Hyg2001652878911508396
  • ArevaloIWardBMillerRSuccessful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulatorClin Infect Dis200133111847185111692295
  • FalcoffETarantoNJRemondeguiCEClinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compoundsTrans R Soc Trop Med Hyg199488195978154019
  • AlmeidaRD’OliveiraAJrMachadoPRandomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous LeishmaniasisJ Infect Dis199918051735173710515844
  • ColerRNGotoYBogatzkiLRamanVReedSGLeish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cellsInfect Immun20077594648465417606603
  • BadaroRLoboIMunosAImmunotherapy for drug-refractory mucosal leishmaniasisJ Infect Dis200619481151115916991091
  • ConvitJUlrichMZerpaOImmunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990–1999Trans R Soc Trop Med Hyg200397446947215259484
  • GonzalezUPinartMRengifo-PardoMMacayaAAlvarJTweedJAInterventions for American cutaneous and mucocutaneous leishmaniasisCochrane Database Syst Rev20092CD00483419370612
  • TiumanTSSantosAOUeda-NakamuraTFilhoBPNakamuraCVRecent advances in leishmaniasis treatmentInt J Infect Dis2011158e525e53221605997
  • MiguelDCYokoyama-YasunakaJKUlianaSRTamoxifen is effective in the treatment of Leishmania amazonensis infections in micePLoS Negl Trop Dis200826e24918545685